期刊
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
卷 1506, 期 1, 页码 98-117出版社
WILEY
DOI: 10.1111/nyas.14710
关键词
bacterial engineering; biosensor; CAR T cells; cell therapy; cellular engineering; CRISPR; gene therapy; genetic engineering; logic gating; oncolytic virus; receptor engineering; synthetic biology; tumor-associated antigen
资金
- NUS Medicine Synthetic Biology Translational Research Programme [NUHSRO/2020/077/MSC/02/SB]
- Agency for Science, Technology and Research (A*STAR) of Singapore [112 177 0040]
- U.S. Air Force [FA/2, 386/12/1/4, 055]
- U.S. Defense Threat Reduction Agency [HDTRA1-13-0037]
- National Research Foundation of Singapore [NRF-NRFI05-2019-0004]
- Synlogic Inc.
- European Research Council [803150]
- Swiss Cancer Research [KFS-4593-08-2018]
- NIH [NS102807, ES02530, ES029136, AI126880, AI149699]
- NMSS [RG4111A1, JF2161-A-5]
- International Progressive MS Alliance [PA-1604-08459]
- Jennifer Oppenheimer Cancer Research Initiative
- National Institute of Biomedical Imaging and Bioengineering [R01EB024562]
- School of Biological and Health Systems Engineering of the Ira
- Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine [NIH/NIDDK P30DK120531]
- Pfizer-MIT RCA Synthetic Biology Program (CHO2.0 and Precision Post-Translational Modification)
- NIH Ruth L. Kirschstein NRSA postdoctoral fellowship [5T32HL007208]
- Agencia Espanola de Investigacion (AEI/MICIU/FEDER, EU) [BIO2017-89081-R]
- CSIC-SynLogic [20182256]
- European Research Council (ERC) [803150] Funding Source: European Research Council (ERC)
Synthetic biology has the potential to transform cell- and gene-based therapies by engineering cells to selectively respond to disease signals, sparing healthy tissue from potential harm.
Synthetic biology has the potential to transform cell- and gene-based therapies for a variety of diseases. Sophisticated tools are now available for both eukaryotic and prokaryotic cells to engineer cells to selectively achieve therapeutic effects in response to one or more disease-related signals, thus sparing healthy tissue from potentially cytotoxic effects. This report summarizes the Keystone eSymposium Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics, which took place on May 3 and 4, 2021. Given that several therapies engineered using synthetic biology have entered clinical trials, there was a clear need for a synthetic biology symposium that emphasizes the therapeutic applications of synthetic biology as opposed to the technical aspects. Presenters discussed the use of synthetic biology to improve T cell, gene, and viral therapies, to engineer probiotics, and to expand upon existing modalities and functions of cell-based therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据